gip and glp-1 receptors receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read The Effects of Dual GLP-1/GIP

But coverage isn't the full story

Discovery of an NAD(+) analogue with enhanced specificity for PARP1 [PMID: 35308855] Laboratory literature summary: Discovery of an NAD(+) analogue with enhanced specificity for PARP1

For inflammatory bowel disease, mesalamine, corticosteroids, immunomodulators (azathioprine, methotrexate), and biologics (infliximab, adalimumab, vedolizumab, ustekinumab) all have Level 1 evidence from Phase III trials with thousands of patients

The majority of current studies on Dihexa are preclinical (animal or lab-based), but the findings are compelling: While human data is still emerging, functional medicine practitioners are already seeing anecdotal benefits across multiple domains, including energy and vitality

Let your glow shine from within

Brain protection by reeratrol and fenofibrate against stroke requieres peroxsiome proliferator-activated receptor alpha in mice